Loading
Latest filing published 08 Sept 2023 for Arch Therapeutics, Inc., €2,610. Read the official filing
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Michael S. Abrams is a declared insider of Arch Therapeutics, Inc., with filings sourced from SEC (Form 4). We count 2 filings; the first trade dates from 6 July 2022 and the latest from 31 August 2023.
The open-market record is one-sided, with 1 purchase worth €2,610 and not one sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 1 share grant. In 2023 alone, the filings show 1 purchase and no sales.
The newest entry dates from 8 September 2023: an open-market purchase of €2,610, in Arch Therapeutics, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations